23 terminated. 23 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Terminated 23 |
| Phase 2 | 3 | Terminated 3 |
Follow Neurodevelopmental Disorders: new trials by email Literature Review of Neurodevelopmental Disorders trials Research Report on Neurodevelopmental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules - Attention Deficit Hyperactivity Disorder | Phase 3 | Terminated | Ironshore Pharmaceuticals and Development, Inc | 26 | 2024-09-13 | 2025-11-06 |
| Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD NRCT-101SR - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 2 / Phase 3 | Terminated | Neurocentria, Inc. | 95 | 2024-01-25 | 2026-01-15 |
| Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders amitriptyline - Autism Spectrum Disorder, Repetitive Compulsive Behavior | Phase 3 | Terminated | University of Missouri, Kansas City | 1 | 2023-11-01 | 2025-05-30 |
| Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Methylphenidate, Matching Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 3 | 2019-05-07 | 2022-04-25 |
| Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions Memantine Hydrochloride, Placebo - Autism, Autism Spectrum Disorder | Phase 3 | Terminated | Massachusetts General Hospital | 25 | 2018-11-13 | 2026-02-25 |
| Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. BUMETANIDE (S95008) for week 0 - 26, PLACEBO for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52 - Autism Spectrum Disorder (ASD) | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 211 | 2018-10-04 | 2023-06-05 |
| Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder Bumetanide Oral Solution, Placebo - Autism Spectrum Disorder (ASD) | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 211 | 2018-09-24 | 2024-07-25 |
| A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension Balovaptan, Placebo - Autism Spectrum Disorder | Phase 3 | Terminated | Hoffmann-La Roche | 322 | 2018-08-08 | 2021-10-27 |
| Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment SPN-810, Placebo - Attention Deficit Hyperactivity Disorder | Phase 3 | Terminated | Supernus Pharmaceuticals, Inc. | 41 | 2018-07-31 | 2024-04-24 |
| Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents TEV-50717, Placebo - Tourette Syndrome | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 228 | 2018-05-25 | 2021-11-09 |
| Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) SHP465 - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Terminated | Shire | 141 | 2018-01-02 | 2021-06-03 |
| Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4) SPN-810 - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Terminated | Supernus Pharmaceuticals, Inc. | 491 | 2016-04-01 | 2024-05-16 |
| Intervention for Teens With ADHD and Substance Use Brief Early Intervention, Parent Training with Adolescent Cognitive Behavioral Therapy, Methylphenidate - Attention Deficit Hyperactivity Disorder | Phase 3 | Terminated | Florida International University | 158 | 2015-07-01 | 2023-03-22 |
| Oxytocin in Adolescents With Autism Spectrum Disorders OCYTOCINA - SPRAY NASAL - Autism Spectrum Disorder | Phase 2 / Phase 3 | Terminated | University of Sao Paulo General Hospital | 30 | 2015-06-01 | 2019-10-28 |
| The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD MDX, Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Terminated | Alcobra Ltd. | 283 | 2015-06-01 | 2017-01-19 |
| Omega-3 Fatty Acids Supplementation in ADHD Omega-3 Fatty Acids Supplementation, Omega-3 Placebo - ADHD | Phase 3 | Terminated | University Hospital, Basel, Switzerland | 8 | 2013-04-01 | 2015-06-24 |
| Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders STX209 (arbaclofen) - Autism Spectrum Disorders | Phase 3 | Terminated | Seaside Therapeutics, Inc. | 165 | 2011-11-01 | 2013-07-31 |
| Efficacy Study of Polyunsaturated Fatty Acids in Children and Adolescents With Attention Deficit/ Hyperactivity Disorder ω-3 fatty acids suspension, placebo suspension - ADHD | Phase 3 | Terminated | Johannes Gutenberg University Mainz | 284 | 2011-03-08 | 2017-09-20 |
| Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits Vyvanse, fMRI, Placebo - Traumatic Brain Injury, Attention Deficit Disorder | Phase 3 | Terminated | Vanderbilt University | 22 | 2009-10-01 | 2017-05-19 |
| A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder Edivoxetine - Attention Deficit Hyperactivity Disorder | Phase 2 / Phase 3 | Terminated | Eli Lilly and Company | 267 | 2009-09-01 | 2019-10-08 |
Showing 20 of 23. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (12) · Autism Spectrum Disorder (7) · Autistic Disorder (6) · Tourette Syndrome (2) · Brain Injuries, Traumatic (1) · Marijuana Abuse (1) · Social Skills (1) · Spasm (1) · non-verbal learning disabilities (1)
Mental Disorders (23) · Attention Deficit and Disruptive Behavior Disorders (12) · Child Development Disorders, Pervasive (9) · Nervous System Diseases (4) · Brain Diseases (3) · Central Nervous System Diseases (3) · Autism Spectrum Disorder (2) · Basal Ganglia Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Heredodegenerative Disorders, Nervous System (2) · Movement Disorders (2) · Neurodegenerative Diseases (2) · Tic Disorders (2)
Methylphenidate (3) · Bumetanide (2) · Amitriptyline (1) · BID protein, human (1) · Fluoxetine (1) · Lisdexamfetamine Dimesylate (1) · Memantine (1) · Oxytocin (1) · Pramipexole (1) · Secretin (1) · Suspensions (1) · alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol (1) · balovaptan (1) · deutetrabenazine (1)
Institut de Recherches Internationales Servier (2) · Supernus Pharmaceuticals, Inc. (2) · Alcobra Ltd. (1) · Assistance Publique - Hôpitaux de Paris (1) · Boehringer Ingelheim (1) · Eli Lilly and Company (1) · Florida International University (1) · Hoffmann-La Roche (1) · Ironshore Pharmaceuticals and Development, Inc (1) · Johannes Gutenberg University Mainz (1) · Massachusetts General Hospital (1) · Neurocentria, Inc. (1) · Neuropharm (1) · Repligen Corporation (1) · Seaside Therapeutics, Inc. (1)
United States (17) · France (4) · Italy (4) · Spain (4) · Brazil (3) · Canada (3) · Germany (3) · Hungary (3) · Poland (3) · United Kingdom (3) · Australia (2) · Portugal (2) · Argentina (1) · Colombia (1) · Czechia (1)
Gagan Joshi, MD (1) · Gianpiera Ceresoli-Borroni, PhD (1) · Guosong Liu, MD, PhD (1) · Helena P. Brentani, PHD (1) · Jeffrey Newcorn, MD (1) · Jessica A. Hellings, MD (1) · Michael G Tramontana, Ph.D. (1) · Michael Huss, Prof. Dr. (1) · Paul Wang, M.D. (1) · Peyret Emmanuelle, PHD (1)
PMID 39816573, PMID 35151410, PMID 35201607, PMID 36006807, PMID 37058600, PMID 37794745, PMID 37811711, PMID 41198718
2017 (2), 2008 (1), 2016 (1)